lp533401 has been researched along with Chronic-Kidney-Disease-Mineral-and-Bone-Disorder* in 1 studies
1 other study(ies) available for lp533401 and Chronic-Kidney-Disease-Mineral-and-Bone-Disorder
| Article | Year |
|---|---|
The use of LP533401 as a therapeutic option for renal osteodystrophy affects, renal calcium handling, vitamin D metabolism, and bone health in uremic rats.
Klotho is a key regulator of phosphate and Ca. We evaluated the effect of LP533401 therapy on Klotho-expression-dependent Ca. Treatment with LP533401 and its vehicle resulted in the inhibition of transient receptor potential vanilloid receptor subtypes 5 and 6 (TRPV5, TRPV6) and calbindin (CaBP-28k, CaBP-9k) expression. The compensatory acceleration in renal expression of Na+/Ca. The modulation of circulating serotonin and its relation to other regulators of calcium handling can play an important role in calcium homeostasis and bone integrity in CKD rats treated with LP533401. Topics: Animals; Bone and Bones; Calcium; Chronic Kidney Disease-Mineral and Bone Disorder; Disease Models, Animal; Glucuronidase; Klotho Proteins; Male; Pyrimidines; Rats; Rats, Wistar; Renal Insufficiency, Chronic; Uremia; Vitamin D | 2019 |